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Abstract
Introduction: Celiac disease (CD) prevalence is increasing but the disorder remains undiagnosed. The study compares CD serology markers reque-
sted by General Practitioners (GPs) over time and geographical areas. The aim of the current research is to assess the inter-practice and temporal 
variability in the request of CD serology markers by GPs in Spain, and the differences between regions.
Materials and methods: A cross-sectional study was conducted enrolling Spanish clinical laboratories. Primary care CD serology markers request 
in 2010, 2012 and 2014 from 15 autonomous communities (AACC), with more participants was reported. Test-utilization rates were calculated (tissue 
transglutaminase IgA antibodies (tTG-IgA) and deaminated peptide gliadine IgA antibodies (DGP-IgA) per 1000 inhabitants), and also the ratio of 
both tests request (DGP-IgA /tTG-IgA).
Results: The request of tTG-IgA per 1000 inhabitants increased significantly along years (from 3.99 to 5.90 (P < 0.001)). The demand of DGP-IgA per 
1000 inhabitants was maintained in  2010 and 2012 (0.68 and 0.6), and decreased in 2014 (0.35) (P = 0.927). DGP-IgA /tTG-IgA diminished over time 
(from 0.16 to 0.06 (P = 0.548)), and in the 2014 edition, there was a significant regional difference, ranging from 0.01 to 0.57 (P < 0.001).
Conclusions: The variability in the request in CD serology markers emphasizes the need of inter-regional cooperation to develop strategies to opti-
mize the use of laboratory tests.
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Celiac disease (CD) is an immune-mediated small 
intestinal enteropathy that is activated by expo-
sure to dietary gluten in genetically predisposed 
individuals. Originally CD was considered a rare 
malabsorption syndrome affecting mainly chil-
dren, but nowadays it has been recognized as a 
common condition that may be diagnosed at any 
age (1). CD is characterized by the presence of a va-
riety of gluten-dependent clinical manifestations, 
specific antibodies of CD, haplotypes HLA-DQ2 
and/or HLA-DQ8 and enteropathy. 
Traditionally patients presented with malabsorp-
tion but over time the proportion of newly diag-
nosed patients with malabsorptive symptoms 
have decreased and even asymptomatic or pa-
tients with variable non-gastrointestinal findings 
have increased (2). Patients with CD can present 
with a wide range of symptoms and signs, and are 
classically diagnosed through a positive serology 
and ulterior duodenal biopsy while consuming a 
gluten-containing diet. Due to the diversity of the 
clinical symptoms, presentation at any age and 
the increasing prevalence, CD is more often diag-
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nosed in primary care by the General Practitioners 
(GPs) who serve as the patients’ first point of con-
tact (3).
The disease prevalence varies considerably, is in-
creasing worldwide and many patients with CD 
still remain undiagnosed (4). In fact it is estimated 
that in 2020 there will be 5 million cases of CD cas-
es just in the Mediterranean area (5).
Specific antibodies of CD are tissue transglutami-
nase IgA antibodies (tTG-IgA), endomysial IgA anti-
bodies (EmA), and the deamidated gliadin peptide 
IgA antibodies (DGP-IgA).
Since publication of the European Society of Pae-
diatric Gastroenterology and Nutrition (ESPGHAN) 
guidelines in year 2012, tTG-IgA antibody is the 
preferred single test for detection of CD (6). Tests 
that measure DGP-IgA may be used as additional 
tests in patients who are negative for other CD-
specific antibodies but in whom clinical symptoms 
raise a strong suspicion of CD, especially if they are 
younger than 2 years. In subjects with humoral IgA 
deficiency, at least 1 additional test measuring IgG 
class CD-specific antibodies should be done (6).
The diversity of clinical symptoms and the increas-
ing prevalence emphasize the need for strategies 
for the optimal detection of patients. A first step 
would be to study how appropriately CD serology 
is requested in primary care. A previous study has 
shown a higher variability in the rarely requested 
tests in primary care, in a population covering 
around 38% of the Spanish population (7). 
We hypothesized that there is a high variability in 
the use of serological markers of CD in Primary 
Care. Thus, the aim of this study is to assess the in-
ter-practice and temporal variability in the re-
quests of serological markers of CD from primary 




A cross-sectional study was conducted at the na-
tional level, enrolling clinical laboratories belong-
ing to the Autonomous Communities (AACC) of 
Spain, all of which operate under the Spanish Na-
tional Health Service, which is responsible for the 
majority of the national population. All applicable 
residents have free access to their primary care 
physician and to the hospital. 
The study was designed and conducted at the 
University Hospital of San Juan de Alicante, where 
a questionnaire (Supplementary material) was de-
veloped and used to collect different variables 
from Spanish laboratories: number of tests per-
formed from the Laboratory Information Systems 
Patient’s databases and organizational data in 
three different years. In 2010 a call for data was 
posted on the Redconlab website, and also via 
email in the Redconlab 2012 study. In the edition 
of 2014, the dissemination of the questionnaire 
was also addressed through a LinkedIn (https://
w w w. l i n ke d i n . co m / i n /r e d co n l a b - g r u p o -
a5663bb7) group. In the three different years, or 
editions, participation in the REDCONLAB study 
was voluntary. In all, 37, 76 and 110 laboratories, on 
a voluntary basis, participated in the 2010, 2012 
and 2014 editions.
Methods
Numbers of tTG-IgA and DGP-IgA, requested by all 
the GPs for the years 2010, 2012 and 2014 from lab-
oratories at different health departments (HD) 
across Spain were reported in the three studies. 
Test-utilization rates were calculated. Rates were 
expressed as tests (tTG-IgA and DGP-IgA) per 1000 
inhabitants, and also through the ratio of both 
tests requests (DGP-IgA /tTG-IgA). The three edi-
tions results were compared. 
In the 2014 edition, laboratories were grouped in 
the different AACC, when more than 4 partici-
pants, and a group joining the results of the rest. 
AACC were codified by numbers due to confiden-
tiality, and DGP-IgA/tTG-IgA ratio was calculated. 
Statistical analysis 
The analysis of the distribution of the indicators 
was conducted by Kolmogorov-Smirnov test. The 
numerical data (tTG-IgA and DGP-IgA per 1000 in-
habitants, and the ratio of both tests requests 
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(DGP-IgA /tTG-IgA), are presented as median (in-
terquartile range). The differences in the indicators 
between years and AACC were calculated using 
the Kruskal-Wallis test analysis. A two-sided P ≤ 
0.001 rule was utilized as the criterion for rejecting 
the null hypothesis of no difference. All statistical 
analyses were carried out with SPSS version 22.0 
(SPSS, Chicago, IL, USA).
Results
Table 1 shows the data of all participants and also 
the descriptive analysis of the three indicators in 
the three editions. 
The request of tTG-IgA expressed per 1000 inhab-
itants increased along years from 3.99 to 5.90 (P < 
0.001). On the other hand, the demand of DGP-IgA 
was maintained in the first two editions, and de-
creased in the third, although this difference was 
not statistically significant. The DGP-IgA/tTG-IgA 
ratio mildly diminished over time. 
The 2014 edition joined 10 AACCS with more than 
4 participants (in alphabetical order: Andalucía, 
Canarias, Castilla La Mancha, Castilla Leon, Extrem-
adura, Galicia, Madrid, Murcia, País Vasco and Va-
lencia). An eleventh group was created with those 
AACC that did not reach the 4 participants (in al-
phabetical order: Aragon, Asturias, Baleares, Can-
tabria and Cataluña).
Figure 1 shows graphically the DGP-IgA/tTG-IgA 
indicator results for year 2014 in the different 
AACC; there was a significant difference between 
regions, ranging from 0.01 to 0.57 (P < 0.001). 
Discussion
As expected, the primary care anti-tTG request in-
creased along years and the ratio DGP-IgA/tTG-
IgA decreased. No decrease was observed in the 
request of DGP-IgA in the first two editions, de-
spite its request should have been limited to pa-
tients less than two years of age. There were big 
regional differences in the DGP-IgA/anti-tTG-IgA 
indicator result.  
Although participants did not state if they imple-
mented guidelines or not, the increment in tTG-
IgA request along years was according to the 
guidelines for the diagnosis of CD. It took, howev-
er, more time to observe a subsequent decreased 
in the requests in DGP-IgA. It is true that the illness 
is more frequently detected in children, but the 
rates of DGP-IgA request seemed excessive at least 
in the first two editions, taking into account that 
only 2.85% of the Spanish population is younger 
than 2 years (8). Conversely, 6 AACCs showed very 
low results in that indicator, suggesting an earlier 
adoption of the new guidelines. However, the dif-




Centers, N 37 76 110
AACC, N 8 13 15
Inhabitants attended, N 8,130,334 17,679,195 27,434,262
Total DGP-IgA, N 8530 34,371 38,178
Total tTG-IgA, N 34,996 86,962 169,097
DGP-IgA/1000 inhabitants 0.68 (2.08) 0.60 (2.51) 0.35 (2.03) 0.927
tTg-IgA/1000 inhabitants 3.99 (3.20) 4.37 (3.45) 5.90 (4.30) < 0.001
DGP-IgA/tTG-IgA ratio 0.16 (0.76) 0.12 (0.76) 0.06 (0.46) 0.548
AACC - Autonomous communities. tTG-IgA - tissue transglutaminase IgA antibodies. DGP-IgA - deamidated gliadin peptide IgA 
antibodies. Results are presented as median (interquartile range). The differences in the indicators between years were calculated 
using the Kruskal-Wallis test analysis. P ≤ 0.001 was considered statistically significant.
Table 1. Data and descriptive analysis of indicators in the three REDCONLAB editions
Biochemia Medica 2017;27(1):231–6  http://doi.org/10.11613/BM.2017.025 
234
Salinas M. et al. Differences in celiac disease serological markers
IgA indicator results suggest that is probably due 
to different requesting customs in the different 
AACCs, or maybe different timing in the imple-
mentation of new clinical guidelines.
Our research is the first to study how CD serologi-
cal tests are used over time in CD, a disorder prone 
to active case-finding strategy in primary care, to 
effectively improve its diagnostic rate (9).
Our results show that there is a need for a faster 
dissemination of scientific evidence, especially 
when it deals with a common and relevant disor-
der such as CD. In fact, an early diagnosis is clini-
cally relevant, as possible evolution of undiag-
nosed cases include non-Hodgkin’s Lymphoma, 
carcinomas or refractory CD. Our study also shows 
that the establishment of strategies is crucial to 
reach a homogeneous, appropriate and efficient 
request of diagnostic tests. There are interven-
tions, that once designed through the application 
of scientific evidence and consensus with GPs, 
could be maintained over time, such as computer-
aided algorithms that could substitute inappropri-
ate tests for meaningful ones, as, in this case DGP-
IgA for tTG-IgA when the patient is older than 2 
years (10). 
The main limitation of the study is that the differ-
ences in test requesting patterns, could be ex-
plained by case mix variations or groups of pa-
tients requiring similar tests, procedures, and re-
sources, and also the number of children and 
adults among habitants attended in the different 
HD or AACC. 
The variability in the request in CD serology mark-
ers, the delay in the demand of appropriate tests 
and the significant difference between AACC em-
phasize the need to improve communication and 
to establish interventions to enhance the appro-






















P value1 2 3 4 5 6 7 8 9 10 11
Centers (N) 20 16 10 11 12 5 5 6 6 5 14
Median 0.05 0.57 0.01 0.05 0.00 0.00 0.01 0.06 0.19 0.02 0.32
< 0.001
IQR 0.56 0.96 0.15 0.12 0.01 0.05 0.04 0.08 0.68 0.78 0.9
IQR – interquartile range. AACC - Autonomous communities. The differences in the indicator between years was calculated using 
the Kruskal-Wallis test analysis. P ≤ 0.001 was considered statistically significant. 
Figure 1. Bloxpot of ratio of tests requests (DGP-IgA /tTG-IgA) in different AACC. 
tTG-IgA - tissue transglutaminase IgA antibodies. DGP-IgA - deamidated gliadin peptide IgA antibodies. AACC - Autonomous com-
munities. º - outlier. * - extreme value.
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departmental and inter-regional cooperation 
would be crucial to develop strategies in order to 
optimize the use of laboratory tests.
Acknowledgements
Members of the REDCONLAB working group are 
the following: Vidal Perez Valero (Hospital Region-
al Universitario de Malaga, Hospital Universitario 
Virgen de la Victoria); Félix Gascón (Hospital Valle 
de los Pedroches, Malaga, Pozoblanco); Isidoro 
Herrera Contreras (Complejo Hospitalario de Jaen); 
Maria Angeles Bailen Garcia (Hospital Universitario 
Puerta del Mar de Cadiz); Cristobal Avivar Oyo-
narte (Hospital de Poniente, El Ejido); Esther Roldán 
Fontana (A.G.S. de Osuna); Fernando Rodriguez 
Cantalejo (Hospital Universitario Reina Sofia de 
Cordoba); Jose Angel Noval Padillo (Hospital Uni-
versitario Virgen del Rocio); M Angela Gonzalez 
García (AGS Norte de Cadiz); Ignacio Vazquez Rico 
(Hospital Juan Ramon Jimenez de Huelva); Cristina 
Santos (Hospital Rio Tinto); Angeles Giménez Ma-
rín (Hospital de Antequera); Maria del Señor López 
Vélez (Hospital San Cecilio de Granada), Jose Vi-
cente Garcia Larios (Hospital Virgen de las Nieves, 
Granada); Federico Navajas Luque (AGS Este de 
Málaga-Axarquía); Amado Tapia (Hospital de Bar-
bastro); Maria Esther Sole LLop (Hospital de Al-
cañiz); Juan José Puente (Hospital Clínico Universi-
tario Lozano Blesa); Patricia Esteve (Hospital Ernest 
Lluch); Maria Teresa Avello Lopez (Hospital San 
Agustín-Aviles, Hospital Valle del Nalon); Emilia 
Moreno Noguero (Hospital Can MIsses); Ana Maria 
Follana Vazquez (Hospital Mateu Orfila); Jose Luis 
Ribes Valles (Hospital de Manacor); Mª Luisa 
Fernández de Lis Alonso (Area de Salud de 
Fuerteventura); Cecilia Martin (Hospital Nuestra 
Señora de la Candelaria, Tenerife); Leopoldo Mar-
tin Martin (Hospital General de la Palma); Miguel 
Angel Pico Picos (Hospital Universitario de Canari-
as); Casimira Dominguez Cabrera (Hospital Univer-
sitario de Gran Canaria Dr Negrín); Marta Riaño 
Ruiz (Hospital Insular de Gran Canaria); Juan Igna-
cio Molinos (Hospital Sierrallana de Torrelavega); 
Luis Fernando Colomo (Hospital de Laredo); Mar-
cos Lopez Hoyos (Hospital Universitario Marques 
de Valdecilla); Enrique Prada de Medio (Hospital 
Virgen de la Luz de Cuenca); Pilar Garcia Chico 
(Hospital General Universitario de Ciudad Real); Si-
mon Gomez-Biedma (Hospital General de Alman-
sa); Vicente Granizo Dominguez (Hospital Universi-
tario de Guadalajara); Guadalupe Ruiz (Complejo 
Hospitalario de Toledo); Laura Navarro (Complejo 
Hospitalario Universitario de Albacete); Fidel Velas-
co Pena (Hospital Virgen de Altagracia, Man-
zanares); Carolina Andrés Fernandez (Hospital 
General de Villarobledo); Joaquín Domínguez Mar-
tinez y Oscar Herráez Carrera; Mª Carmen Lorenzo 
Lozano (Hospital de Puertollano); Maria Teresa Gil 
(Hospital Nuestra Señora del Prado Talavera de la 
Reina); Mª Angeles Rodriguez Rodriguez (Comple-
jo Asistencial Universitario de Palencia (Hospital 
Rio Carrion); M. Victoria Poncela Garcia (Hospital 
Universitario de Burgos); Luis Rabadan (Complejo 
Asistencial de Soria); Vicente Villamandos (Hospital 
Santos Reyes, Aranda del Duero); Nuria Fernandez 
Garcia (Hospital Universitario Rio Hortega-Vallado-
lid); Jose Miguel Gonzalez Redondo (Hospital San-
tiago Apostol de Miranda de Ebro); Cesareo Garcia 
(Hospital Universitario de Salamanca); Luis Garcia 
Menendez (Hospital El Bierzo); Pilar Alvarez Sastre 
(Complejo Asistencial de Zamora); Ovidio Gomez 
(Hospital Cínico Universitario de Valladolid); Mabel 
LLovet (Hospital Universitario Verge de la Cinta 
(Tortosa)); Nuria Serrat (Hospital Joan XXIII de Tar-
ragona); Mª José Baz (Hospital de Llerena, Bada-
joz); Maria Jose Zaro (Hospital Don Benito-Vil-
lanueva); M Carmen Plata (Hospital Campo 
Arañuelo, Navalmoral de la Mata); Pura Garcia Yun 
(Área de Salud de Badajoz (Hospital Infanta Cristi-
na, Hospital Perpetuo Socorro y Hospital Materno 
Infantil); Milagrosa Macías Sánchez (Area de Salud 
de Caceres (Complejo Hospitalario San Pedro de 
Alcantara); Javier Martin (Hospital Virgen del Puer-
to de Plasencia); Lola Máiz Suarez (Hospital Lucus 
Augusti, Lugo); Berta Gonzalez Ponce (Hospital Da 
Costa, Burela); Aida Perez Fuertes (Hospital Arqui-
tecto Marcide, El Ferrol); M. Amalia Andrade Olivie 
(Hospital Xeral-Cies, CHU Vigo); Pastora Rodriguez 
(Hospital Universitario de A Coruña); M. Mercedes 
Herranz Puebla (Hospital General Universitario 
Gregorio Marañon); Antonio Buño Soto (Hospital 
Universitario La Paz, Madrid); Fernando Cava (BR 
Salud); Tomas Pascual (Hospital Universitario 
Raquel Guillén Santos de Getafe); Carmen Hernan-
Biochemia Medica 2017;27(1):231–6  http://doi.org/10.11613/BM.2017.025 
236
Salinas M. et al. Differences in celiac disease serological markers
do de Larramendi (Hospital Severo Ochoa de Le-
ganes); Raquel Blázquez Sánchez (Hospital de 
Mostoles); Pilar Díaz (Hospital 12 de Octubre, Ma-
drid); Ana Díaz (Hospital Universitario de La Princ-
esa); Marta Garcia Collia (Hospital Ramon y Cajal, 
Madrid); Maria Angeles Cuadrado Cenzual (Hospi-
tal Clinico San Carlos); Santiago Prieto (Hospital 
Universitario de Fuenlabrada); María Menchero del 
Carmen Gallego Ramírez (Hospital Rafael Mendez, 
Lorca); Jose Luis Quilez Fernandez (Hospital Uni-
versitario Reina Sofia de Murcia); Maria Dolores Al-
baladejo (Hospital Santa Lucia, Cartagena); Maria 
Luisa Lopez Yepes (Hospital Virgen del Castillo de 
Yecla); Alfonso Pérez Martínez (Hospital Morales 
Meseguer); Antonio López Urrutia (Hospital de 
Cruces, Bilbao); Adolfo Garrido Chércoles (Hospital 
Universitario de Donostia); Carmen Mar Medina 
(Hospital Galdakao-Usonsolo); M Carmen Zugaza 
(Unidad de Gestion Clinica de Alava); Patxi Aguayo 
(Hospital Universitario de Basurto); Silvia Pesudo 
(Hospital La Plana); Carmen Vinuesa (Hospital de 
Vinaros); Julian Díaz (Hospital Francesc de Borja, 
Gandia); Marisa Graells (Hospital General Universi-
tario de Alicante); Diego Benitez Benitez (Hospital 
de Orihuela); Arturo Carratala (Hospital Clinico Uni-
versitario de Valencia); Consuelo Tormo (Hospital 
General de Elche); Francisco Miralles (Hospital Lluis 
Alcanyis, Xativa); Amparo Miralles (Hospital de Sa-
gunto); Jose Luis Barberà (Hospital de Manises); 
Juan Molina (Hospital Comarcal de La Marina, Vil-
lajoyosa); Martin Yago (Hospital de Requena); 
Mario Ortuño (Hospital Universitario de la Ribera 
(Alzira)); Maria Jose Martinez Llopis (Hospital de 
Denia); Nuria Estañ (Hospital Dr. Peset); Ricardo 
Molina (Hospital Virgen de los Lirios, Alcoy); Juan 
Antonio Ferrero (Hospital General de Castellon); 
Begoña Laiz Marro (Hospital Universitario y Po-
litecnico La Fe de Valencia); Goitzane Marcaida 
(Consorcio Hospital General Universitario de Va-
lencia).
Potential conflict of interest
None declared.
References 
 1. Rampertab SD, Pooran N, Brar P, Singh P, Green PH. Trends in 
the presentation of celiac disease. Am J Med 2006;119:355.
e9. https://doi.org/10.1016/j.amjmed.2005.08.044.
 2. Lindfors K, Koskinen O, Kaukinen K. An update on the dia-
gnostics of celiac disease. Int Rev Immunol 2011;30:185-96. 
https://doi.org/10.3109/08830185.2011.595854.
 3. Husby S, Koletzko S, Korponay-Szabo I, Mearin L, Philips A, 
Shamir R, et al. ESPGHAN guidelines for the diagnosis for ce-
liac disease in children and adolescents. An evidence-ba-
sed approach. J Pediatr Gastroenterol Nutr 2012;54:136-60. 
https://doi.org/10.1097/MPG.0b013e31821a23d0.
 4. Murray JA, Van Dyke C, Plevak MF, Dierkhising RA, Zinsmei-
ster AR, Melton LJ 3rd. Trends in the identification and clini-
cal features of celiac disease in a North American commu-
nity, 1950-2001. Clin Gastroenterol Hepatol 2003;1:19-27. 
https://doi.org/10.1053/jcgh.2003.50004.
 5. Greco L, Timpone L, Abkari A, Abu-Zekry M, Attard T, 
Bouguerrà F, et al. Burden of celiac disease in the Mediterra-
nean area. World J Gastroenterol 2011;17:4971-8. https://
doi.org/10.3748/wjg.v17.i45.4971.
 6. Rashid M, Lee J. Serologic testing in celiac disease: Practical 
guide for clinicians. Can Fam Physician 2016;62:38-43.
 7. Salinas M, López-Garrigós M, Flores E, Uris J, Leiva-Sali-
nas C; Pilot Group of the Appropriate Utilization of Labora-
tory Tests. Larger differences in utilization of rarely reque-
sted tests in primary care in Spain. Biochem Med (Zagreb) 
2015;25:410-5. https://doi.org/10.11613/BM.2015.041.
 8. Instituto Nacional de Estadística. Available at: http://www.
ine.es/. Accessed June 29th 2016.
 9. Catassi C, Kryszak D, Louis-Jacques O, Duerksen DR, Hill I, 
Crowe SE, et al. Detection of celiac disease in primary care: 
a multicenter case-finding study in North America. Am J 
Gastroenterol 2007;102:1454-60. https://doi.org/10.1111/
j.1572-0241.2007.01173.x.
10. Salinas M, López-Garrigós M, Asencio A, Leiva-Salinas M, 
Lugo J, Leiva-Salinas C. Laboratory utilization improve-
ment through a computer-aided algorithm developed with 
general practitioners. Clin Chem Lab Med 2015;53:1391-7. 
https://doi.org/10.1515/cclm-2014-0762.
